Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.48 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18570624 | 0.77 | SCN8A (0.50) | SCN8ASCN10AHTR2AHTR2CHTR2B | |
| SCHEMBL24154948 | 0.77 | TAS2R14 (0.56) | SLC22A12CYP2D6SLC6A2SLC6A4NOS2 | |
| SCHEMBL30319921 | 0.77 | TAS2R14 (0.56) | SLC22A12CYP2D6SLC6A2SLC6A4NOS2 | |
| SCHEMBL2657080 | 0.76 | CYP1A2 (0.46) | SCN8ASCN10ASLC22A12HTR2AHTR2C | |
| SCHEMBL25373566 | 0.76 | AR (0.46) | SCN8ASCN10ASLC22A12CYP2D6SLC6A2 | |
| SCHEMBL4661838 | 0.76 | SCN8A (0.62) | SCN8ASCN10AHTR2AHTR2CHTR2B | |
| SCHEMBL3294014 | 0.73 | SLC22A12 (0.45) | SLC22A12 | |
| SCHEMBL5656320 | 0.73 | AR (0.50) | CYP2D6SLC6A2SLC6A4NOS2AR | |
| SCHEMBL3578065 | 0.72 | AR (0.52) | CYP2D6SLC6A2SLC6A4NOS2AR | |
| SCHEMBL6545410 | 0.72 | ADORA2A (0.50) | SLC22A12NOS2CYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841483-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841483-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841483-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2004596-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120647-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070238733-A1 | Drugs for various disorders such as sodium channel modulators, cardiovascular disorders, antiarrhythmia agents ar nervous system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-11 | — | — | US | disclosed |
| US-20070238733-A1 | Drugs for various disorders such as sodium channel modulators, cardiovascular disorders, antiarrhythmia agents ar nervous system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-11 | — | — | US | disclosed |
| US-20070238733-A1 | Drugs for various disorders such as sodium channel modulators, cardiovascular disorders, antiarrhythmia agents ar nervous system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238733-A1 | Drugs for various disorders such as sodium channel modulators, cardiovascular disorders, antiarrhythmia agents ar nervous system disorders | KCNH1, SCN5A, CACNA1A | SCN8A 70/4885SCN10A 47/4885SLC22A12 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.